Setting a standard for venous thromboembolism prophylaxis

American Journal of Health-System Pharmacy

Volumn 58, Issue SUPPL. 2, 2001, Pages

  Turpie, A G G ^a  

^a HAMILTON GENERAL HOSPITAL   (Canada)

Author keywords

Anticoagulants; Drug comparisons; Enoxaparin; Org 31540; SR 90107A; Surgery; Thromboembolism; Toxicity

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 9; COUMARIN ANTICOAGULANT; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN; THROMBIN; THROMBIN INHIBITOR;

ANTICOAGULANT THERAPY; ANTICOAGULATION; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; HEPARINIZATION; HIP FRACTURE; HUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK MANAGEMENT; STANDARDIZATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS; TREATMENT OUTCOME;

EID: 0034757221     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/58.suppl_2.s18     Document Type: Conference Paper

References (24)

1. Structure and biological activity of heparin
2. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery
3. Anticoagulant drugs in the treatment of pulmonary embolism: A controlled trial
4. Prevention of venous thromboembolism
5. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety
6. Prevention of venous thromboembolism in orthopaedics in the United States
7. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals from the Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association
8. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range
9. Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540)
10. Heterogeneity of unfractionated heparins studied in connection with species, source, and production processes
11. The unique antithrombin III binding domain of heparin: A lead to new synthetic antithrombotics
12. SR 90107A/Org 31540, a novel anti-factor Xa antithrombotic agent
13. Heparin sequencing brings structure to the function of complex oligosaccharides
14. Importance of a 3-O-sulfate group in a heparin pentasaccharide for antithrombotic activity
15. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement
16. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide
17. Pentasaccharide SR90107A/Org31540 (PS) clinical trials update: Lessons for practice
18. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement
19. The PENTATHLON 2000 study: Comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin in the prevention of venous thromboembolism (VTE) after elective hip replacement surgery
20. The PentaMaks study: Comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin: The prevention of venous thromboembolism (VTE) after elective major knee surgery
21. The EPHESUS Study: Comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin (LMWH) for the prevention of venous thromboembolism (VTE) after elective hip replacement surgery
22. The Penthifra Study: Comparison of the first synthetic factor Xa inhibitor with low molecular weight Heparin (LMWH) for the prevention of venous thromboembolism (VTE) after hip fracture surgery
23. The first synthetic factor Xa inhibitor, pentasaccharide Arixtra/Xantidar, compared with low molecular weight heparin to prevent venous thromboembolism after orthopedic surgery
24. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SRg0107A/ORG31540) with pure anti-factor Xa activity: A phase II evaluation